Core Insights - Korro Bio, Inc. has received approval to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) in Australia [1][2] - The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110, with the first participant dosing expected in Q1 2025 and completion anticipated in 2026 [1][4] Company Overview - Korro Bio is focused on developing a new class of genetic medicines using its proprietary RNA editing platform, OPERA™, targeting both rare and prevalent diseases [6][7] - KRRO-110 is the first RNA editing oligonucleotide candidate from Korro, designed to edit the SERPINA1 RNA to restore normal AAT protein secretion [6] Study Details - The REWRITE study will involve up to 64 participants, including healthy adults and clinically stable AATD patients with the PiZZ genotype [3] - Secondary and exploratory endpoints will include pharmacokinetic and pharmacodynamic parameters to guide optimal dose selection for future studies [3] Clinical Expectations - Interim readout for the study is expected in the second half of 2025, focusing on participants with the PiZZ genotype [4] - The study's design aims to demonstrate the potential of KRRO-110 in patients at risk for serious lung and liver complications despite standard treatment [2][9]
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency